Which treatment comes first? study seeks to optimize neuroendocrine tumor therapy
NCT ID NCT07534371
First seen Apr 21, 2026 · Last updated May 12, 2026 · Updated 3 times
Summary
This study looks at 500 people with advanced neuroendocrine tumors to find the best order of two treatments: surufatinib and somatostatin analogs. Researchers compare starting with surufatinib then switching to somatostatin analogs versus the opposite order. The goal is to see which sequence helps patients live longer without their cancer getting worse.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NEUROENDOCRINE TUMORS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
West China Hospital, Sichuan University
Chengdu, Sichuan, 610041, China
Conditions
Explore the condition pages connected to this study.